EN DE

MPH Health Care AG (93M1) Fair Value & Analysis

Financial Services · DE · Market cap €104M

MH MPH Health Care AG 93M1 · XETRA
Price€24.20
Fair Value€48.80
Upside+101.7%
Quality68/100
Watch MPH Health Care AG for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -58.5% net margin
Low debt · generates free cash flow
20.33% dividend yield
Ranks above peers (9/13)
Moderate moat 48/100
Evidence: High Range €36.60 – €61.00 Share as image

Fair value as of: Jul 19, 2026

From 12 valuation models · updated 21 days ago

Fair value updated Jul 19, 2026, revised from €58.00 to €48.80 (−15.9%) since Jun 26, 2026. Share price +1.4% over the past month.

A solid business, screening 102% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (€36.60). The market is more pessimistic than our downside scenario.
  • Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality.
  • For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

€26.38 €6.86 Fair Value €48.80 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range €6.86 – €26.38 · fair‑value band €36.60 – €61.00 · the €24.20 price screens below the €48.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

MPH Health Care AG (93M1) currently trades at €24.20, while our model-based Fair Value estimate is €48.80, implying the stock looks roughly 101.7% undervalued today. The Quality Score stands at 68/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

It earns a return on equity of -43.4%. Net debt stands at €10.6M. Fundamentals as of Jul 19, 2026

Our scenario range runs from €36.60 (bear case) to €61.00 (bull case); at €24.20, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 63% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -12% fair-value upside, at 102%, 93M1 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF €0.2600 80
Residual Income €47.16 €52.12 €72.10 76
Gordon GGM €8.36 €14.00 €18.17 70
All 12 models by family
DCF Models
Owner Earnings €75.69 €149.22 €277.55 31
5Y P/E Exit €72.53 €186.73 €346.24 38
10Y P/E Exit €45.20 €133.61 €286.70 35
Earnings-Based
Graham-Dodd €46.54 €324.54 €455.44 54
Lynch FV €167.67 €239.53 €311.38 50
Dividend Discount
Gordon GGM €8.36 €14.00 €18.17 70
DDM Multi-Stage €8.36 €13.28 €15.06 61
Multiples
P/E Multiple €112.92 €150.56 €188.20 63
P/B Multiple €87.26 €116.34 €145.43 55
Asset-Based
NCAV (Graham) €28.43 €38.09 €56.85 50
Growth DCF
Growth DCF €0.2600 80
Economic Profit
Residual Income €47.16 €52.12 €72.10 76

Widest divergence: Earnings-Based (€239.53) versus Dividend Discount (€13.28). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) −€13.4M
Revenue growth (YoY) -93.5%
Return on equity -43.4%
Free cash flow €123K FY2025
Operating margin 89.2%
EPS (TTM) €-6.85
More key figures
EPS growth (YoY) -31.0%
Net debt €10.6M FY2025

Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 67 · Market factors (momentum, volatility) 74

Profitability 72
Margins and returns on capital today
Quality Growth 61
Are margins and returns improving?
Cashflow 32
Earnings quality: real cash, not paper profit
Fin. Strength 80
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 32
Calm price path (market factor)
Momentum 89
Price trend over the last 3–12 months (market factor)
52W Momentum 94
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It operates through Beauty, Pharma, and Real Estate segments.

Full company description

MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It operates through Beauty, Pharma, and Real Estate segments. The company offers medical-aesthetic beauty surgeries and treatments, as well as operation and provision of medical infrastructures for partner companies; and sells pharmaceuticals and medical products in the areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. It also provides plastic and aesthetic treatments and surgeries; operates European mail-order pharmacy. In addition, the company is involved in real estate business; acts as an investment manager; renewable energies; and project development, including new residential construction/owner occupied homes. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was incorporated in 2008 and is based in Berlin, Germany.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

MPH Health Care AG reported revenue of €364M in FY2025 versus €4.4M in FY2021, a compound +202.3%/yr. Reported net income was €29.3M in FY2025.

Growth Quality 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
€364M
Latest YoY
+5,860.8%
Avg. growth/yr (3Y)
+276.1%
Avg. growth/yr (16Y)
+11.7%
Revenue +202.3%/yr
FY21 €4.4M
FY22 €6.8M
FY23 €7.2M
FY24 €6.1M
FY25 €364M
Net income
FY21 −€9.0M
FY22 €29.1M
FY23 €29.5M
FY24 €32.0M
FY25 €29.3M

Watch 93M1: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "MPH Health Care AG Fair Value". https://www.fairvalue-calculator.com/stock/93M1

Peer Group

Asset Management · 973 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside +102% · Top 25%
Return on assets 11% · Top 25%
Net margin (TTM) -59% · Bottom 25%
Operating margin (TTM) 98% · Top 25%
Revenue growth -94% · Bottom 25%
Dividend yield (TTM) 20.3% · Top 25%
Debt / equity 0.01× · Lower than median

Valuation Multiples vs Asset Management median · lower = cheaper

P/B 0.50× · Cheaper than 75% of peers
P/S (TTM) 2.41× · Cheaper than median
P/FCF 981.9× · Pricier than 75% of peers
EV/EBITDA 2.5× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 37
FUTURE 0 · sector 6
PAST 0 · sector 26
HEALTH 99 · sector 95
DIVIDEND 100 · sector 69

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
Fondul Proprietatea SA FP $0.0420 $0.0800 +90%
BlackRock, Inc BLK $1,136 $465.75 -59%
Blackstone Inc BX $124.56 $16.35 -87%
Investor AB INVEB kr 423.70 kr 847.40 +100%
Brookfield Corporation BN C$62.45 C$10.12 -84%
KKR & Co KKR $100.94 $44.88 -56%
AB Industrivärden INDUA kr 532.50 kr 1,065 +100%
Jio Financial Services Limited JIOFIN ₹242.98 ₹40.19 -83%
Hedef Holding HEDEF 267.25 TRY 320.98 TRY +20%
Bajaj Holdings BAJAJHLDNG ₹10,398 ₹9,202 -12%

Compare MPH Health Care AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is MPH Health Care AG (93M1) overvalued or undervalued?
As of Jul 19, 2026, our model estimates a fair value of €48.80 versus a price of €24.20, about +102% (undervalued).
What is the fair value of 93M1?
Our model-based fair value for MPH Health Care AG is €48.80 (as of Jul 19, 2026), built from audited fundamentals. The current price is €24.20.
What is the quality score of 93M1?
MPH Health Care AG has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the net profit margin of 93M1?
The net profit margin of MPH Health Care AG is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track MPH Health Care AG and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.